NDAORALTABLET
Approved
Jul 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
6/8 — Strong
BACTRIM (sulfamethoxazole and trimethoprim) by PharmaIN is dihydrofolate reductase inhibitors [moa]. Approved for prosthetic joint infection. First approved in 1973.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BACTRIM is a fixed-dose combination of sulfamethoxazole and trimethoprim, oral antibiotic tablets that work by inhibiting bacterial dihydrofolate reductase, blocking nucleic acid and protein synthesis. It is indicated for prosthetic joint infection and represents a foundational antimicrobial class approved in 1973.
$0.002BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Medicare spending ($2K) signals a mature, commoditized asset with limited commercial team investment opportunities.
Mechanism of Action
Dihydrofolate Reductase Inhibitors
Pharmacologic Class:
Dihydrofolate Reductase Inhibitor Antibacterial
Indications (1)
Clinical Trials (2)
A Non-Interventional Safety Study of Balsamic Bactrim
Started Nov 2016
52 enrolled
Bronchitis
A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis
Started Nov 2016
51 enrolled
Bronchitis
Career Relevance
Worked on BACTRIM at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.